Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05945524

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Conditions

Interventions

TypeNameDescription
OTHERBone marrow samplingBone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Timeline

Start date
2023-09-28
Primary completion
2026-03-31
Completion
2026-05-31
First posted
2023-07-14
Last updated
2025-04-10

Locations

18 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05945524. Inclusion in this directory is not an endorsement.

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination (NCT05945524) · Clinical Trials Directory